Persistent atrial fibrillation
diseaseOn this page
Also known as persistent AF
Summary
Persistent atrial fibrillation (MONDO:1030009) is a disease and 204 clinical trials. Top therapeutic interventions include amiodarone, flecainide, and ibutilide. A subtype of atrial fibrillation — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 204
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | persistent atrial fibrillation |
| Mondo ID | MONDO:1030009 |
| ICD-10-CM | I48.1 |
| ICD-11 | 519924384 |
| SNOMED CT | 440059007 |
| UMLS | C2585653 |
| MedGen | 749907 |
| Is cancer (heuristic) | no |
Also known as: persistent AF
Disease family
This is a subtype of atrial fibrillation. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › heart disorder › cardiac rhythm disease › atrial fibrillation › persistent atrial fibrillation
Related subtypes (2): familial atrial fibrillation, paroxysmal atrial fibrillation
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 204.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 187 |
| PHASE4 | 10 |
| PHASE2 | 4 |
| PHASE3 | 2 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04405258 | PHASE4 | ACTIVE_NOT_RECRUITING | Left Atrial Posterior Wall Additional Isolation for Persistent Atrial Fibrillation Trial |
| NCT06765356 | PHASE4 | ACTIVE_NOT_RECRUITING | Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias |
| NCT07273994 | PHASE4 | RECRUITING | Evaluation of Two Different Regimens of the Antiarrhythmic Drug Amiodarone to Maintain Normal Sinus Rhythm After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation |
| NCT07508618 | PHASE4 | RECRUITING | Study on the Prevention of Atrial Fibrillation Recurrence After Ablation by Qidong Yixin Granule |
| NCT00613496 | PHASE4 | UNKNOWN | Irbesartan and Adhesion Molecules in AF |
| NCT00845780 | PHASE4 | COMPLETED | Withdrawal Versus Continuation of Amiodarone in Successfully Treated Patients With Persistent Atrial Fibrillation |
| NCT01877473 | PHASE4 | WITHDRAWN | Comparison of Reverse Remodeling and PVI Versus CFAE and/or Linear Lesions and PVI for Persistent AF |
| NCT02509754 | PHASE4 | UNKNOWN | Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Impaired Left Ventricular Function |
| NCT02528604 | PHASE4 | COMPLETED | Electrical Cardioversion, Ablation or Pace and Ablate for Persistent Atrial Fibrillation |
| NCT02654353 | PHASE4 | COMPLETED | A New Approach to Target the Substrates of Persistent Atrial Fibrillation: The Sequential Substrate Ablation Approach |
| NCT01362738 | PHASE3 | COMPLETED | Effect of Empirical Left Atrial Appendage Isolation on Long-term Procedure Outcome in Patients With Persistent or Long-standing Persistent Atrial Fibrillation Undergoing Catheter Ablation |
| NCT05723536 | PHASE3 | UNKNOWN | PLAI-AF Trial: Hybrid Endo-epicardial Partial Left Atrial Isolation vs. Endocardial Ablation in Patients With Persistent Atrial Fibrillation |
| NCT01534962 | PHASE2 | COMPLETED | Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion |
| NCT01703247 | PHASE2 | COMPLETED | Ganglionated Plexi Ablation Combined With Pulmonary Vein Isolation |
| NCT02002923 | PHASE2 | UNKNOWN | Pulmonary Vein Isolation Versus Botulinum Toxin Injection Plus Pulmonary Vein Isolation in Patients With Atrial Fibrillation |
| NCT02008448 | PHASE2 | UNKNOWN | Endomyocardial Botulinum Toxin Injection in Patients With Persistent Atrial Fibrillation |
| NCT01483183 | PHASE1 | TERMINATED | Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation |
| NCT02184013 | Not specified | ACTIVE_NOT_RECRUITING | Correlation of the Arrhythmia Mechanism and Substrate to Ablate Persistent Atrial Fibrillation Study |
| NCT03546374 | Not specified | RECRUITING | Medtronic Terminate AF Study |
| NCT03732794 | Not specified | ACTIVE_NOT_RECRUITING | AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment |
| NCT04088071 | Not specified | RECRUITING | Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation |
| NCT04662489 | Not specified | ACTIVE_NOT_RECRUITING | Radial Ablation for the Control of Persistent Atrial Fibrillation |
| NCT05005949 | Not specified | ACTIVE_NOT_RECRUITING | STOP Persistent AF PAS |
| NCT05021601 | Not specified | RECRUITING | Bi-atrial Versus Left Atrial Ablation for Patients With Rheumatic Mitral Valve Disease and Non-paroxysmal Atrial Fibrillation |
| NCT05085860 | Not specified | RECRUITING | Acute Responses to Exercise in Females and Males With Symptomatic Atrial Fibrillation |
| NCT05104658 | Not specified | ACTIVE_NOT_RECRUITING | Heart Rehabilitation for All |
| NCT05264831 | Not specified | RECRUITING | Pulmonary Vein Isolation Alone or in Combination With Substrate Modulation After Electric Cardioversion Failure |
| NCT05411614 | Not specified | RECRUITING | Hybrid Ablation of Atrial Fibrillation in Heart Failure |
| NCT05462145 | Not specified | ACTIVE_NOT_RECRUITING | Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation |
| NCT05776797 | Not specified | RECRUITING | AV Junction Ablation or Optimal Medical Treatment in PatiEnts With Cardiac Resynchronization Therapy and Permanent Atrial Fibrillation |
| NCT05790707 | Not specified | RECRUITING | EfFect of Ablation of Persistent AtriaL Fibrillation on COgNitive Function in Individuals With Mild Cognitive Impairment |
| NCT05826665 | Not specified | RECRUITING | Observational Study to Examine the Procedural and Outcomes of AF Ablation Assisted by STAR Apollo™ Mapping System |
| NCT05922917 | Not specified | ACTIVE_NOT_RECRUITING | Pulsed-field Ablation in Patients With Persistent Atrial Fibrillation |
| NCT05986526 | Not specified | ACTIVE_NOT_RECRUITING | The PIFPAF-PFA Study |
| NCT05988411 | Not specified | RECRUITING | ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients |
| NCT06096246 | Not specified | RECRUITING | Investigation of Cardioversion Versus Therapeutic Ablation for Persistent AF (ORBICA-AF) |
| NCT06096337 | Not specified | ACTIVE_NOT_RECRUITING | Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation |
| NCT06106594 | Not specified | ACTIVE_NOT_RECRUITING | VOLT CE Mark Study |
| NCT06124690 | Not specified | ACTIVE_NOT_RECRUITING | Persistent Atrial Fibrillation Without the Evidence of Low-voltage Areas |
| NCT06134752 | Not specified | ACTIVE_NOT_RECRUITING | Electroporation for Treatment of Atrial Fibrillation |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| AMIODARONE | 4 | 6 |
| FLECAINIDE | 4 | 3 |
| IBUTILIDE | 4 | 2 |
| COLCHICINE | 4 | 1 |
| DRONEDARONE | 4 | 1 |
| IRBESARTAN | 4 | 1 |
| ONABOTULINUMTOXINA | 4 | 1 |
| PROPAFENONE | 4 | 1 |
| RANOLAZINE | 4 | 1 |
| CHEMBL443232 | 0 | 1 |
| CHEMBL4590731 | 0 | 1 |